1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 10 areas
0
News (30d)
Quiet
Amalive Limited is a company with 1 orphan drug designation across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Alstrom syndrome | L-ornithine phenylacetate | Des.TrialAppr. |
| PLIN1-related familial partial lipodystrophy | L-ornithine phenylacetate | Des.TrialAppr. |
| hyperinsulinism-hyperammonemia syndrome | L-ornithine phenylacetate | Des.TrialAppr. |
| hyperlysinuria with hyperammonemia | L-ornithine phenylacetate | Des.TrialAppr. |
| idiopathic hypereosinophilic syndrome | L-ornithine phenylacetate | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio